This implicates BTK activity in immune cell proliferation and activation, features shown to contribute to disease pathology and worsened cognitive decline in NDDs such as AD, PD, and MS (NCT04338061 and NCT04338022). The gene discussed is BTK; the disease is myeloid sarcoma.